Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the single-dose oral bioavailability of Ondansetron 8
mg orally disintegrating tablets of OHM Laboratories Inc (A subsidiary of Ranbaxy
Pharmaceuticals Inc, USA) with Zofran ODT® 8 mg orally disintegrating tablets of
GlaxoSmithKline, USA in healthy, adult, human, male subjects under fasting condition.